U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332533) titled 'A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer' on Dec. 25, 2025.
Brief Summary: This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.
Study Start Date: Dec. 30, 2025
Study Type: INTERVENTIONAL
Condition:
HER2-positive Gastric Cancer
Intervention:
DRUG: KN026
In accordance with the protocol
DRUG: Capecitabine
Capecitabine is for oral administration.
DRUG: Enlonsto...